Literature DB >> 24034659

Medication class effects on visit-to-visit variability of blood pressure measurements: analysis of electronic health record data in the "real world".

Timothy R Smith1, Joseph P Drozda, Jeffrey A Vanslette, Amanda S Hoeffken, Robert A Nicholson.   

Abstract

Blood pressure (BP) visit-to-visit variability (VVV) influences the risk of vascular events and mortality. Research has suggested that antihypertensive medication classes may differentially impact VVV. This study evaluated whether antihypertensive medication class differentially impacted BP VVV among hypertensive individuals in a clinical, "real-world" setting as well as the association between VVV and patient characteristics. Clinical observational data were extracted for adults (mean age, 63; 56% female, 86% Caucasian) with hypertension from the Mercy EpicCare EHR-Derived Database (MEDD) (n=183,374) who had at least 4 outpatient visits with BP readings. A multilevel mixed model for change over time estimated between- and within-subject effects on the absolute real VVV of systolic BP. Diuretics significantly lowered VVV (β=-0.32[-0.39 to-0.25]) and α-/β-blockers resulted in the highest VVV (β=0.89 [0.77-1.00]). Being older, female, and having a higher systolic BP and certain comorbid conditions significantly raised VVV (P<.001). The findings from the MEDD were consistent in general with other research on BP VVV. However, the magnitude of effect of antihypertensive medication class and patient characteristics was relatively low (<10% of the BP VVV variance for any one variable). More research is needed to evaluate the extent to which the class of antihypertensive medication class impacts BP VVV in the outpatient setting. ©2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24034659      PMCID: PMC8033920          DOI: 10.1111/jch.12165

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  18 in total

1.  Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure.

Authors:  O H Klungel; A de Boer; A H Paes; N J Nagelkerke; J C Seidell; A Bakker
Journal:  J Clin Epidemiol       Date:  2000-11       Impact factor: 6.437

2.  When measurements are misleading: modelling the effects of blood pressure misclassification in the English population.

Authors:  Tom Marshall
Journal:  BMJ       Date:  2004-04-17

3.  Prognostic significance of blood-pressure variability.

Authors:  Bas van den Bogaard; Berend E Westerhof; Bert-Jan H van den Born
Journal:  Lancet       Date:  2010-08-07       Impact factor: 79.321

4.  The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994.

Authors:  Paul Muntner; Daichi Shimbo; Marcello Tonelli; Kristi Reynolds; Donna K Arnett; Suzanne Oparil
Journal:  Hypertension       Date:  2011-01-03       Impact factor: 10.190

5.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

Review 6.  Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension.

Authors:  Peter M Rothwell
Journal:  Lancet       Date:  2010-03-13       Impact factor: 79.321

7.  Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population.

Authors:  Edward Pringle; Charles Phillips; Lutgarde Thijs; Christopher Davidson; Jan A Staessen; Peter W de Leeuw; Matti Jaaskivi; Choudomir Nachev; Gianfranco Parati; Eoin T O'Brien; Jaakko Tuomilehto; John Webster; Christopher J Bulpitt; Robert H Fagard
Journal:  J Hypertens       Date:  2003-12       Impact factor: 4.844

8.  Reproducibility of measures of visit-to-visit variability in blood pressure after transient ischaemic attack or minor stroke.

Authors:  S C Howard; P M Rothwell
Journal:  Cerebrovasc Dis       Date:  2009-07-24       Impact factor: 2.762

9.  Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study.

Authors:  Martin J Turner; Johan M van Schalkwyk
Journal:  Am J Hypertens       Date:  2008-01       Impact factor: 2.689

10.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

View more
  10 in total

Review 1.  Visit-to-Visit Variability of Systolic Blood Pressure and Cardiovascular Disease.

Authors:  Wael F Hussein; Tara I Chang
Journal:  Curr Hypertens Rep       Date:  2015-03       Impact factor: 5.369

2.  Rollercoaster Blood Pressure: An Alzheimer Disease Risk Factor?

Authors:  Alexander E Merkler; Costantino Iadecola
Journal:  Circulation       Date:  2017-08-08       Impact factor: 29.690

Review 3.  New Insights into the Role of Visit-to-Visit Glycemic Variability and Blood Pressure Variability in Cardiovascular Disease Risk.

Authors:  Jin J Zhou; Daniel S Nuyujukian; Peter D Reaven
Journal:  Curr Cardiol Rep       Date:  2021-03-02       Impact factor: 2.931

4.  Visit-to-visit variability of systolic blood pressure predicts all-cause mortality in patients received percutaneous coronary intervention with drug-eluting stents.

Authors:  Suk Min Seo; Woo-Baek Chung; Ik Jun Choi; Yoon-Seok Koh; Sang-Hyun Ihm; Pum-Jun Kim; Wook Sung Chung; Ki-Bae Seung
Journal:  Heart Vessels       Date:  2017-11-18       Impact factor: 2.037

5.  The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Authors:  Ian M Kronish; Amy I Lynch; Suzanne Oparil; Jeff Whittle; Barry R Davis; Lara M Simpson; Marie Krousel-Wood; William C Cushman; Tara I Chang; Paul Muntner
Journal:  Hypertension       Date:  2016-05-23       Impact factor: 10.190

6.  Understanding visit-to-visit blood pressure variability.

Authors:  Luis M Ruilope
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-12-11       Impact factor: 3.738

7.  Day-to-Day Blood Pressure Variability and Risk of Dementia in a General Japanese Elderly Population: The Hisayama Study.

Authors:  Emi Oishi; Tomoyuki Ohara; Satoko Sakata; Masayo Fukuhara; Jun Hata; Daigo Yoshida; Mao Shibata; Toshio Ohtsubo; Takanari Kitazono; Yutaka Kiyohara; Toshiharu Ninomiya
Journal:  Circulation       Date:  2017-08-08       Impact factor: 29.690

Review 8.  Association between Variability of Metabolic Risk Factors and Cardiometabolic Outcomes.

Authors:  Min Jeong Park; Kyung Mook Choi
Journal:  Diabetes Metab J       Date:  2022-01-27       Impact factor: 5.376

9.  Medication class effects on visit-to-visit variability of blood pressure measurements: analysis of electronic health record data in the "real world".

Authors:  Timothy R Smith; Joseph P Drozda; Jeffrey A Vanslette; Amanda S Hoeffken; Robert A Nicholson
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-07-12       Impact factor: 3.738

10.  Factors Associated with Visit-to-Visit Variability of Blood Pressure Measured as Part of Routine Clinical Care among Patients Attending Cardiology Outpatient Department of a Tertiary Care Centre in Northern Sri Lanka.

Authors:  Thirunavukarasu Kumanan; Vathulan Sujanitha; Mahesan Guruparan; Nadarajah Rajeshkannan
Journal:  Int J Hypertens       Date:  2019-12-05       Impact factor: 2.420

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.